Emerging Diagnostic Firm Says It Got Mixed Messages From FDA
This article was originally published in The Gray Sheet
Executive Summary
InterGenetics, an early stage firm specializing in genetic tests and RNA-based treatments, complains that it faces an uncertain future after getting conflicting feedback from FDA about marketing its cancer diagnostic
You may also be interested in...
Laboratory Stakeholders Urge FDA To Ditch IVDMIA Guidance, Pursue Rule
FDA should start over in its efforts to claim regulatory oversight of a new class of high-tech laboratory-developed tests through a guidance document and begin a formal rulemaking process, diagnostic industry stakeholders said at a Feb. 8 hearing
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.